Bexion Pharmaceuticals bexionpharma.com


Public list: Pharma Startups (4732) Cancer Therapeutics (1137)

Bexion Pharmaceuticals is a company focused on the development of cures for cancer. Specifically, the company is interested in first entering the clinic with a glioma cancer indication, possibly simultaneously with a leukemia or pancreatic cancer indication.

Bexion Pharmaceuticals is a company focused on the development of cures for cancer. Specifically, the company is interested in first entering the clinic with a glioma cancer indication, possibly simultaneously with a leukemia or pancreatic cancer in...Show all

Company (Alive / Active)

Phone: (+1) 513-807-0574

Fax: (+1) 859-581-3900

632 Russell St
Covington, 41011
Kentucky, United States

Latest News

See more competitors data Competitors
Total Funding Date of Last Funding
Bexion Pharmaceuticals $0.4M Dec 13, 2010
See all 16 competitors

Web Traffic

Rank

Show (-10)

Engagement (PVPU)

Show (+1%)

Domain Authority Score
Show
Page Views Per Million (PVPM)
Show
Reach Per Million
Show

SEO Statistics

Domain Authority Score Show
Page Authority Score Show
No. External Links Show
No. Links Show

Web Traffic Statistics - Growth

Per Week Per Month Per 6 Months Per Year
Rank Login to see details
Page Views Per Million Login to see details
Page Views Per User Login to see details
Reach Per Million Login to see details

Related Bexion Pharmaceuticals Jobs

jobs by Indeed job
						search

Investors

Investor Investor Type Location Participating Rounds
See all 3 investors
There is no Board of Directors data available for this company. Please select another tab.

Competitors

Company Status Description Investors

Tragara Pharmaceuticals

San Diego, California, United States
Alive / ActiveTragara Pharmaceuticals is a pharmaceutical company focused on the clinical and commercial development of drugs for the treatment of various cancers. TG02 is an orally available, small molecule that targets - equipotently - the major signaling pathways involving ERK5, JAK2, and key cell cycle and transcriptional cyclin-dependent kinases (CDKs), with pharmacological and pharmaceutical properties. Preclinical models demonstrate that TG02 has the ability to deplete the short-lived survival proteins...Show allLogin to see details

Inimex Pharmaceuticals

Vancouver, British Columbia, Canada
Alive / ActiveInimex Pharmaceuticals, Inc. is focused on the development and commercialization of Innate Defense Regulators (IDRs), first in class drugs that selectively trigger the body's innate defenses without causing inflammation. IDR products have major market potential for infectious disease, cancer, and inflammatory disease. These products will reduce morbidity and mortality in the rapidly growing population of immune suppressed and elderly patients who are "at-risk" for these disorders. IDR produc...Show allLogin to see details
See all 16 competitors

Patents

Title Application Date Patent Date Status
(Patent / Application)